Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis

References

• Mahler RJ, Adler ML. Clinical review 102: type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 1999;84:1165-1171
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Diabetes Atlas, 3rd edn. Brussels, 2010. Available from: URL:http://www.idf.org/
   Google Scholar
• World Health Organization. Diabetes. Geneva: World Health Organization No 312, 2009. [cited 2010 July 12]. Available from: URL:http://www.who.int/mediacentre/factsheets/fs312/en/index.html
   Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853
   PubMed Web of Science ®Google Scholar
• Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract 2010;87:15-19
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association - Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):i-S140
   Google Scholar
• Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009;180:400-407
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis Canada. Product monograph - Lantus, 2010
   Google Scholar
• Novo Nordisk Canada. Product monograph - Levemir, 2008
   Google Scholar
• Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274
   PubMed Web of Science ®Google Scholar
• Jensen MG, Hansen M, Brock B, et al. Differences between long-acting insulins for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010;11:2027-2035
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
   PubMed Web of Science ®Google Scholar
• Canadian Optimal Medication Prescribing and Utilization Services. An economic evaluation of insulin analogues for the treatment of patients with type 1 and type 2 diabetes mellitus in Canada. Canadian Optimal Medication Prescribing and Utilization Services, 2008. [Cited 2010 July 12]. Available from: URL:http://www.cadth.ca/media/compus/reports/compus_Economic_IA_Report.pdf
   Google Scholar
• Cavallucci S. The top 200. What's making waves in prescription sales. Pharm Pract 2006;22:44-49
   Google Scholar
• Tunis SL, Minshall ME, Conner C, et al. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Curr Med Res Opin 2009;25:1273-1284
   PubMed Web of Science ®Google Scholar
• Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009;31:2086-2097
   PubMed Web of Science ®Google Scholar
• Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007;24:635-642
   PubMed Web of Science ®Google Scholar
• Hollander P, Cooper J, Bregnhoj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-1987
   PubMed Web of Science ®Google Scholar
• Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-548
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2007;51:408-416
   Google Scholar
• Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33:1176-1178
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-40
   PubMed Web of Science ®Google Scholar
• Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-2265
   PubMedGoogle Scholar
• Lee KH, Seo SJ, Smith-Palmer J, et al. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea. Value Health 2009;12(Suppl 3):S55-61
   PubMedGoogle Scholar
• Palmer JL, Knudsen MS, Aagren M, et al. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. J Med Econ 2010;13:212-220
   PubMedGoogle Scholar
• Tunis SL, Sauriol L, Minshall ME. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada. Appl Health Econ Health Policy 2010;8:267-280
   PubMedGoogle Scholar
• Valentine WJ, Aagren M, Haglund M, et al. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scand J Public Health, 2010
   Google Scholar
• Conseil du Médicament, Liste des médicaments, Québec, Modification n°1 comportant la correction n° 2 en vigueur à la meme date, En vigueur le 30 juin 2010. Conseil du Médicament, 2010. Cited 10 A.D. July 13]. Available from: URL:https://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste_Med/Liste_Med/liste_med_mod1_2010_06_30_fr.pdf
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-349
   PubMed Web of Science ®Google Scholar
• Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-2243
   PubMed Web of Science ®Google Scholar
• Edmonton (AB): Alberta Health and Wellness. Health costing in Alberta: 2006 annual report. Edmonton (AB): Alberta Health and Wellness, 2010. Available from: URL:www.health.gov.ab.ca/resources/publications/Health_Costing_2006.pdf
   Google Scholar
• Hart HE, Redekop WK, Berg M, et al. Factors that predicted change in health-related quality of life were identified in a cohort of diabetes mellitus type 1 patients. J Clin Epidemiol 2005;58:1158-1164
   PubMedGoogle Scholar
• Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001;27:347-351
   PubMed Web of Science ®Google Scholar
• Manns B TMSF. Sevelamer in patients with end-stage renal disease: a systematic review and economic evaluation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2010
   Google Scholar
• O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-1038
   PubMed Web of Science ®Google Scholar
• O'Reilly D HRBGCPHJGJ. Development of an Ontario diabetes economic model (ODEM) and application to a multidisciplinary primary care diabetes management program. Hamilton (ON): Program for Assessment of Technology in Health, McMaster University/St Joseph’s Healthcare Hamilton, 2006
   Google Scholar
• Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-112
   PubMedGoogle Scholar
• Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005;21:1617-1629
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43:736-749
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-420
   PubMed Web of Science ®Google Scholar
• Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458-463
   PubMed Web of Science ®Google Scholar
• Statistics Canada. The Consumer Price Index. Statistics Canada, 2010. Available from: URL:http://www.statcan.gc.ca/pub/62-001-x/62-001-x2010005-eng.pdf
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada, 3rd edn. Ottawa (ON): CADATH Publications, 2006. Available from: URL:http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf
   Google Scholar
• Halpern EF, Weinstein MC, Hunink MG, et al. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000;20:314-322
   PubMed Web of Science ®Google Scholar
• Dailey G, Admane K, Owens D. Comparing insulin glargine (GLAR) with insulin detemir (DET) – effects of A1c lowering on weight change and insulin dose in patients (Pts) with type 2 diabetes (T2D). Program and abstracts of the. American Diabetes Association 69th Scientific Sessions; June 5-9, 2009; New Orleans, Louisiana. Poster 480-P. 2009
   Google Scholar
• Pscherer S, Dietrich ES, Dippel FW, et al. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. Int J Clin Pharmacol Ther 2010;48:129-137
   PubMedGoogle Scholar
• Pscherer S, Dietrich ES, Dippel FW, et al. Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany. Ger Med Sci 2010;8: Doc17
   PubMedGoogle Scholar
• Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-2452
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). CEDAC Final Recommendation - Insulin Detemir Resubmission #2 -- Indication: Type 1 or Type 2 Diabetes Mellitus in Adults. 2009
   Google Scholar
• Canadian Optimal Medication Prescribing and Utilization Services. Optimal Therapy Recommendations for the Prescribing and Use of Insulin Analogues. 2. 2009. Canadian Agency for Drugs and Technologies in Health (CADTH)
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. World Health Organization, 2010. [Cited 10 A.D. July 13]. Available from: URL:http://www.whocc.no/atc_ddd_index/
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Acetylsalicylic acid administration following acute myocardial infarction: Guidelines. CADTH, 2010. [Cited 10 A.D. July 13]. Available from: URL:http://www.cadth.ca/media/pdf/k0186_aspirin_post-mi_treatment_htis1-5.pdf
   Google Scholar